Congenital Cytomegalovirus infection (CCMV) is the most common intrauterine infection and affects 0.3%-2.5% of live births. [1] It is estimated that in the case of a primary infection, the risk of mother-to-child transmission is 24%-75%, while during reactivation of CMV infection, the risk is only about 1%. [1, 2] Clinical manifestations of CCMV after birth are observed in 10% of infected newborns. The typical symptoms include intrauterine growth retardation, microcephaly, intracranial calcification, jaundice, hepatosplenomegaly, haemorrhagic rash and chorioretinitis. In 5%-10% of neonates with asymptomatic CCMV, there will be sensorineural hearing loss (SNHL), disorders of speech and developmental delay. [2] [3] [4] Early diagnosis of CCMV is hindered by the lack of a screening programme for CMV infection in pregnant women, the high number of asymptomatic infections in neonates and the uncharacteristic clinical signs of the disease.
We described an intraventricular haemorrhage (IVH) as an early CCMV symptom in a full-term newborn with a normal haemostasis.
casE rEPOrt
A newborn male was born of an uncomplicated first pregnancy with physiological delivery at 41 weeks of gestation and was assessed with APGAR scores 4, 8 and 10 points at the 1 st , 5 th and 10 th min of life, respectively. His birth weight was 3620 g, length was 57 cm and head circumference was 34 cm. In Poland, every newborn has a routine postnatal ultrasound scan of his/her head performed on the 1 st day of life and, in this case, an intraventricular haemorrhage Grade I/II was detected. On a physical examination, tremors and hypertonia were observed. Laboratory test results revealed a platelet count of 164 × 10 3 /µl (normal range: 130-350 × 10 3 /µl), prothrombin time of 13.8 s (normal range: 12.5-16.5 s), prothrombin index of 105.0% (normal range: 80.0%-120.0%) and international normalised ratio of 0.95 (normal range: 0.90-1.30). An ophthalmological examination and hearing screening were normal.
On the 10 th day of life, a second ultrasound scan was performed due to the diagnosis of generalised convulsions and respiratory disorders. This trans-fontanelle ultrasonography showed progression of IVH from Grade I/II to III/IV and hyperechoic changes of the thalamic arteries (lenticulostriate vasculopathy [LSV]). In a head computer tomography, Grade III of IVH, periventricular calcification of white matter, asymmetric ventricular enlargement with Evans index 40% and cyst size of 11 mm × 8 mm in the left lateral ventricle and cyst size of 7 mm × 4 mm in the right lateral ventricle were revealed [ Figure 1 ]. Convulsions and progression of IVH were the reasons for external drainage of the cerebral ventricles. Cerebrospinal fluid (CSF) was dark yellow, cloudy with clots and, after centrifugation, it became yellow and clear. In CSF sediment, protein of 144.7 mg/dl, glucose of 24.0 mg/dl, chlorides of 117.3 mmol/L, pleocytosis of 134/3 FR, erythrocytes of 256/3 FR and haemoglobin were detected. CSF cultures were negative before and after surgery. Traumatic bleeding was excluded radiologically. Metabolic diseases, toxoplasmosis, congenital bacterial infection, clotting disturbances and abnormalities of platelets were also excluded. CMV-DNA in CSF and plasma and urine taken in the 3 rd week of age gained, respectively, 9.96 × 10 2 and 5.63 × 10 3 and 7.69 × 10 6 copies/ml. CCMV was diagnosed and ganciclovir (GCV) treatment was administered.
GCV treatment was started at a dose of 6 mg/kg intravenously every 12 h. After 19 days of treatment, the external drainage was removed and a Rickhama tank was applied. GCV treatment was continued for 42 days. During the treatment, every 7 days, the peripheral blood count as well as liver and kidney function was monitored, and an ultrasound examination was performed. After the end of the 6-week treatment, CMV-DNA in plasma was 1.55 × 10 2 /ml and in urine, it was 1.32 × 10 5 /ml. It was decided to extend the treatment for a further 4 weeks. The therapy was well tolerated, without haematologic complications or hepatic or kidney dysfunction. CMV-DNA in plasma was undetectable, while in urine, it was found at <150 copies/ml.
The ultrasound image of the head was stable, with no increase in Evans index. Brainstem-evoked response audiometry was performed every 3 months, and the auditory thresholds rated on both sides were correct. In the ophthalmic examinations performed every 3 months, there were no inflammatory lesions of the choroid or retina.
In his 1 st year of life, the boy was rehabilitated using the Vojta method. At 13 months, he was crawling, walking in his cot and saying single words. At 16 months, he walked on his own and followed simple instructions. On a physical examination, minor right-handed hemiparesis, a staggering wide-based gait and incoordination were found. The laboratory tests did not reveal abnormalities in blood counts nor in liver or kidney function. Plasma CMV-DNA remained undetectable at 20 months of age.
DiscussiOn
Diagnosis of CCMV is already possible during foetal life, as abnormalities in children can be detected by ultrasound. The method is widely available and allows the recognition of microcephaly, ventricular enlargement, calcification and intracerebral bleeding.
The CCMV risk group are the children of mothers with confirmed seroconversion of anti-CMV immunoglobulin (Ig) M/IgG during pregnancy. It was demonstrated that the presence of anti-CMV did not correlate significantly with CMV-DNA in maternal blood, and the presence of CMV-DNA in the plasma of pregnant women is not synonymous with foetal infection. Thus, the risk of transmission of CMV infection to the foetus should be evaluated based on the amniotic fluid using the polymerase chain reaction (PCR) method during amniocentesis performed after 20 weeks of gestation. According to the Guerra et al's. study, we can observe symptomatic infection of newborns by CMV-DNA >10 5 copies/1 ml of amniotic fluid. [4] Due to the possibility of acquired CMV infection in early infancy, it is necessary to establish the diagnosis up to the 21 st day of the newborn's life. It is recommended to detect CMV in urine or saliva using the PCR method. [5] In the group of children with CCMV, symptomatic central nervous system (CNS) disease is present in 80% and manifests as psychomotor retardation, epilepsy, microcephaly, hydrocephalus, abnormal magnetic resonance or ultrasound image such as intracranial calcification, dilatation of brain ventricles and cortical atrophy. In addition, in these children, inflammatory changes and the presence of CMV-DNA in the CSF can provide confirmation.
In the described case, progressive IVH, LSV, lateral ventricle cyst, ventricular enlargement, intracranial calcification and convulsions on the 10 th day of life led to the diagnosis of CCMV. The presence of CMV-DNA in plasma, urine and CSF confirmed congenital CMV infection. On the basis of laboratory tests, thrombocytopenia and coagulation disorders were excluded. In accordance with the current recommendations, intravenous antiviral therapy was introduced with GCV. Microcephaly, inflammatory changes and the presence of CMV-DNA in the CSF, as well as abnormalities of the CNS imaging, are considered to be poor prognostic factors in the neurological development of children. [6] The most serious complication of CCMV is SNHL, which is diagnosed in approximately 50% of newborns in hearing screening. [7] In our patient, in spite of symptomatic CNS disease, there was no confirmation of impaired hearing in the initial screening and subsequent 3-monthly tests.
Analysis of published data shows that IVH in the course of CCMV relates mainly to preemies or newborns with thrombocytopenia induced by infection. [8, 9] We found only one article describing a newborn with CCMV and IVH with a normal platelet count and coagulation profile. Similar to the case in the report of Suksumek et al., our patient was a full-term baby from a physiological delivery without thrombocytopenia, but with IVH after birth. [10] It should therefore be considered, if an isolated IVH in the CNS in a full-term infant, without delivery complications or abnormalities in the coagulation system, should provide an indication for diagnostics for CCMV. It seems to be important because intraventricular bleeding is found in 3.5% of infants and, in 25% of these cases, pathogenic factors cannot be defined. [9] It is also known that in patients with CCMV, CNS vasculitis occurs, which in turn can lead to haemorrhage or thrombosis, with no sign of coagulation disorders or thrombocytopenia. [8] In the case of the patient discussed here, diagnostic tests performed following the direction of the TORCH in the 2 nd week of life, after the progression of IVH, led to the diagnosis of CCMV infection and its successful treatment.
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